BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)

• Status: Terminated
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels. This study will also look at the pharmacokinetic data (amount of Kaletra in blood at different times).

• Phase: Phase 4

Details

• Lead Sponsor: Community Research Initiative of New England
• Collaborator: Abbott
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• CD4 Count >50

• Viral load 200-75,000 on two most recent measures

• More than 16 weeks on standard dose Kaletra (LPV/r)

• May be initial PI regimen or prior PI usage

• Up to 50-fold resistance to LPV/r

Exclusion Criteria:

• Age < 18 years old